CC
IONS icon

Cannell & Co’s Ionis Pharmaceuticals IONS Stock Holding History

Cannell & Co’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,850
Closed -$227K – 252
2020
Q2 		$227K Buy
+3,850
New +$214K 0.01% 221
2020
Q1 		– Sell
-3,850
Closed -$233K – 238
2019
Q4 		$233K Hold
3,850
– – 0.01% 224
2019
Q3 		$231K Hold
3,850
– – 0.01% 219
2019
Q2 		$247K Hold
3,850
– – 0.01% 218
2019
Q1 		$313K Hold
3,850
– – 0.01% 214
2018
Q4 		$208K Buy
+3,850
New +$196K 0.01% 225

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Cannell & Co's IONS Position: Q3 2020 in Review

Cannell & Co sold out of Ionis Pharmaceuticals (IONS) in Q3 2020, closing a stake of 3,850 shares — an estimated $227K sold.

Cannell & Co first reported a position in IONS in Q4 2018 and held it in 6 quarters. The position peaked at $313K in Q1 2019. 367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

  • Cannell & Co reported no remaining Ionis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Cannell & Co sold 3,850 Ionis Pharmaceuticals shares in Q3 2020, an estimated $227K.
  • Cannell & Co first reported a position in Ionis Pharmaceuticals in Q4 2018 and held it in 6 quarters.
  • Cannell & Co's Ionis Pharmaceuticals position peaked at $313K in Q1 2019.
  • 367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on Cannell & Co's 13F filing for Q3 2020, filed 12 Nov 2020.